Long-term Integrated Safety of Patisiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

This study aims to describe the long-term comprehensive, integrated safety data from the patisiran clinical development program in patients with hATTR amyloidosis with polyneuropathy.

Source: Journal of Cardiac Failure - September 30, 2020 Category: Cardiology Authors: Julian Gillmore, John Berk, Angela Dispenzieri, Michael Polydefkis, Alejandra Gonzalez-Duarte, Yoshiki Sekijima, Marianne T. Sweetser, Seth Arum, Jing Jing Wang, Matthew T. White, Mathew Maurer Tags: 188 Source Type: research